Publications by authors named "Akram Ansarifar"
Article Synopsis
- The study examined the rates of re-fracture and overall mortality in patients over 50 who suffered hip fractures from minor trauma within one year.
- Conducted at a Tehran hospital, the research included 945 patients from 2013 to 2019, revealing a mortality rate of 17.69% in the first year post-fracture, with higher rates in men.
- The study found that 5.03% of patients experienced a re-fracture in the same time frame, highlighting the need for prevention strategies for hip fractures in the elderly.
Background: We conducted a phase III, non-inferiority trial comparing safety and efficacy of RCP recombinant spike protein Covid-19 vaccine to BBIBP (Sinopharm).
Methods: Adult Iranian population received RCP or BBIBP in a randomized, double blind and an additional non-randomized open labeled trial arms. Eligible participants signed a written informed consent and received two intramuscular injections three weeks apart.
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
BMC Med
February 2024
Article Synopsis
- Booster vaccinations are essential to enhance and sustain immunity against COVID-19, especially against new variants, and the study focused on the Razi Cov Pars (RCP) vaccine as a booster for individuals previously vaccinated with the BBIBP-CorV vaccine.
- The clinical trial involved 483 adults, examining the safety and immune response to RCP compared to BBIBP-CorV by measuring neutralizing antibody levels and specific IgG antibodies over time.
- Results showed that RCP significantly boosted neutralizing antibodies, increasing them approximately 21 times higher than baseline, and provided a favorable safety profile for participants.
Background: The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity.
Methods And Findings: In this double-blind, placebo-controlled, phase I trial, we randomly assigned 135 healthy adults between 18 and 55 to receive vaccine strengths of 5 or 10 μg/dose or placebo (adjuvant only) in 0-14 or 0-21 schedules. This trial was conducted in a single center in a community setting.
Background: This study explores the safety and immunogenicity of the Razi-Cov-Pars (RCP) SARS Cov-2 recombinant spike protein vaccine.
Method: In a randomized, double-blind, placebo-controlled trial, adults aged 18-70 were randomly allocated to receive selected 10 µg/200 µl vaccine strengths or placebo (adjuvant). It included two intramuscular injections at days 0 and 21, followed by an intranasal dose at day 51.
Background: We compared Fakhravac and BBIBP-Corv2 vaccines in a phase III trial.
Method: We conducted a multicenter, parallel-group, active-control, non-inferiority clinical trial with pragmatic considerations assessing the safety and efficacy of Fakhravac and BBIBP-Corv2 vaccines. We started with two randomized double-blind arms and added two non-randomized open-label arms (based on participant preference) because of slow recruitment.
Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial.
Vaccines (Basel)
February 2023
: This study aimed to determine the safety and immunogenicity of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). : We conducted a randomized, double-blind, placebo-controlled, phase I trial. Three vaccine strengths were compared with an adjuvant-only preparation.
View Article and Find Full Text PDFPhase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
BMC Infect Dis
February 2023
Article Synopsis
- * In the trial, 500 participants were divided into two groups, receiving either the vaccine or a placebo, and their immune responses and side effects were monitored for up to six months.
- * Results showed that the vaccine significantly increased neutralizing antibody levels compared to the placebo, with common side effects being mild and primarily involving tender injections and headaches, indicating the vaccine's safety and effectiveness.
Background: We performed a multicenter, randomized open-label trial in patients with moderate to severe Covid-19 treated with a range of possible treatment regimens.
Methods: Patients were randomly assigned to one of three regimen groups at a ratio of 1:1:1. The primary outcome of this study was admission to the intensive care unit.
Water-pipe tobacco smoking is harmful to health, yet its rate of prevalence remains uncertain. Recent evidence has shown that the prevalence of water-pipe smoking among students is higher than in the general population. In this study, a systematic review of related literature on water-pipe use was conducted, and for this purpose, 76 articles were examined in the study.
View Article and Find Full Text PDFBackground: Iran's population is aging. Disability is a major public health problem for older adults, not only in Iran but all over the world. The purpose of this study was to investigate the relationship between cardio-metabolic and socio-demographic risk factors and disability in people 60 years and older in Iran.
View Article and Find Full Text PDFBackground: We examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment of SARS-CoV-2.
Methods: We did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) and oxygen saturation (SpO) of less than 93% were enrolled.